Skip to main content
3SBio Inc. logo

3SBio Inc. — Investor Relations & Filings

Ticker · 1530 ISIN · KYG8875G1029 LEI · 529900P0TQC1E9Y7FN31 HKEX Manufacturing
Open in API
Filings indexed 1,491 across all filing types
Latest filing 2021-03-11 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1530

About 3SBio Inc.

http://www.3sbio.com

3SBio Inc. is a biopharmaceutical enterprise specializing in the integrated research, development, production, and commercialization of innovative biopharmaceutical products. The company operates as a biotechnology firm, focusing on the discovery, development, manufacture, and marketing of biologics, with a particular emphasis on mammalian cell-based biopharmaceuticals. 3SBio addresses critical medical needs by providing an extensive range of products and services to markets both domestically and internationally.

Recent filings

Filing Released Lang Actions
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from the company 3SBio Inc. regarding a scheduled board meeting to consider and approve the annual results for the year ended 31 December 2020 and the payment of a final dividend. It does not contain the actual annual results or financial data but merely notifies the market of the upcoming board meeting where these matters will be discussed. The document length is only 1377 characters, which is quite short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement about a report (annual results) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2021-03-11 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February 2021
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related activities for the month ended 28/02/2021. The content focuses on share capital changes, share options, convertible bonds, and other equity-related movements. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is a regulatory filing reporting monthly movements in securities and share capital, which aligns with a capital or financing update rather than a full financial report or announcement of voting results. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement of a report.
2021-03-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 28/02/2021 and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions during the month. The content focuses on changes in share capital and securities issued, with no financial performance data, earnings, or management discussion. This type of document is a regulatory filing reporting share capital movements and is not a full financial report, earnings release, or management report. It is not an announcement of a report but a periodic regulatory return. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-03-01 English
PRELIMINARY RESULTS OF SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2020
Earnings Release Classification · 95% confidence The document is an announcement of preliminary financial results for the year ended 31 December 2020 of a subsidiary company, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. It provides key unaudited financial data extracted from the subsidiary's preliminary results but does not contain a full annual report or detailed financial statements. The document is relatively short (3523 characters) and includes a note that the full preliminary results are published on the Shanghai Stock Exchange website. This indicates that the document is an announcement of financial results rather than the full report itself. The document is not a full Annual Report (10-K) or Interim Report (IR) but rather a preliminary results announcement. Given the nature and length, it fits best under the category of Earnings Release (ER), which is the initial announcement of periodical financial results with key highlights only. FY 2020
2021-02-26 English
PROFIT WARNING
Earnings Release Classification · 95% confidence The document is a profit warning announcement by Hongkong Chinese Limited, indicating an expected consolidated loss for the nine months ended 31 December 2020. It references unaudited financial results and states that the final results will be announced later. The document is short (2937 characters) and serves as an early alert to shareholders and investors about expected financial performance, not a full financial report or detailed earnings release. It does not contain actual financial statements or detailed analysis, but rather a cautionary statement about anticipated results. Therefore, it fits the category of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. 9M 2020
2021-02-24 English
OVERSEAS REGULATORY ANNOUNCEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement related to a share incentive plan and a proposed share grant by a subsidiary of the company. It references regulatory rules (Rule 13.10B of the Listing Rules of the Hong Kong Stock Exchange) and provides links to disclosures on the Shanghai Stock Exchange website. The document is short (2210 characters) and primarily serves to inform about the approval and ongoing updates of a share grant plan. It does not contain financial statements, detailed financial data, or management discussion. It is not a full report but an announcement of regulatory compliance and share incentive plan progress. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-02-24 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.